Effect of tafamidis on left atrial function of patients with transthyretin amyloid cardiomyopathy
- PMID: 38743105
- DOI: 10.1007/s00380-024-02402-9
Effect of tafamidis on left atrial function of patients with transthyretin amyloid cardiomyopathy
Abstract
Transthyretin amyloid cardiomyopathy (ATTR-CM) is characterized by the functional and structural effects of amyloid infiltration, predominantly within the ventricles, causing biventricular wall thickening. Amyloid infiltration can be observed in the left atrium in ATTR-CM patients, but the association of left atrial (LA) myocardial function with cardiovascular events and of changes in LA myocardial function with tafamidis administration have not yet been clarified. Our aim was, therefore, to use speckle-tracking strain for investigating LA myocardial function in patients with ATTR-CM treated with tafamidis. We studied 55 patients with biopsy-proven ATTR-CM who had been treated with tafamidis (age: 76 ± 2 years, male: 93%). For speckle-tracking analysis of LA myocardial function, the systolic LA strain (LA reservoir function) was defined for this study as LA myocardial function from the apical 4-chamber view. The primary endpoint was defined as a composite comprising cardiovascular death and/or heart failure hospitalization after tafamidis administration over a median follow-up period of 28 ± 4 months. Patients with baseline LA strain < 8.6% (median value) experienced significantly more cardiovascular events than those without (log-rank P = 0.002). Moreover, LA strain in 26 patients worsened after tafamidis administration, and multivariate logistic regression analysis showed age, global longitudinal strain and relative apical longitudinal strain index were identified as independent determinants of deterioration of LA strain after tafamidis administration. In conclusion, baseline LA reservoir function is closely associated with cardiovascular events after tafamidis administration, and could be an additional parameter for the management of patients with ATTR-CM.
Keywords: Echocardiography; Left atrial function; Tafamidis; Transthyretin amyloid cardiomyopathy.
© 2024. Springer Nature Japan KK, part of Springer Nature.
Similar articles
-
Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).Am J Cardiol. 2021 Jun 1;148:146-150. doi: 10.1016/j.amjcard.2021.02.035. Epub 2021 Mar 3. Am J Cardiol. 2021. PMID: 33667442 Clinical Trial.
-
Impact of tafamidis on myocardial function and CMR tissue characteristics in transthyretin amyloid cardiomyopathy.ESC Heart Fail. 2024 Oct;11(5):2759-2768. doi: 10.1002/ehf2.14815. Epub 2024 May 12. ESC Heart Fail. 2024. PMID: 38736040 Free PMC article.
-
Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy.Ann Pharmacother. 2020 May;54(5):470-477. doi: 10.1177/1060028019888489. Epub 2019 Nov 18. Ann Pharmacother. 2020. PMID: 31735059 Review.
-
Recovery of right ventricular function in patients with transthyretin cardiac amyloidosis after one-year tafamidis administration.Int J Cardiovasc Imaging. 2025 Jan;41(1):93-101. doi: 10.1007/s10554-024-03293-7. Epub 2024 Nov 28. Int J Cardiovasc Imaging. 2025. PMID: 39607611
-
Tafamidis in the Treatment of ATTR-related Cardiomyopathy: Indications and Grey Zones.Heart Fail Clin. 2024 Jul;20(3):333-341. doi: 10.1016/j.hfc.2024.03.007. Epub 2024 Apr 12. Heart Fail Clin. 2024. PMID: 38844304 Review.
Cited by
-
Comparing Effects of Tafamidis in Controlling Left Ventricular and Left Atrial Strains in Patients With Wild-Type Transthyretin Amyloid Cardiomyopathy.Circ Rep. 2025 Jun 14;7(7):562-567. doi: 10.1253/circrep.CR-25-0066. eCollection 2025 Jul 10. Circ Rep. 2025. PMID: 40642552 Free PMC article.
References
-
- Nochioka K, Quarta CC, Claggett B, Roca GQ, Rapezzi C, Falk RH, Solomon SD (2017) Left atrial structure and function in cardiac amyloidosis. Eur Heart J Cardiovasc Imaging 18:1128–1137 - PubMed
-
- Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C, Investigators A-AS (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379:1007–1016 - DOI - PubMed
-
- Kitaoka H, Izumi C, Izumiya Y, Inomata T, Ueda M, Kubo T, Koyama J, Sano M, Sekijima Y, Tahara N, Tsukada N, Tsujita K, Tsutsui H, Tomita T, Amano M, Endo J, Okada A, Oda S, Takashio S, Baba Y, Misumi Y, Yazaki M, Anzai T, Ando Y, Isobe M, Kimura T, Fukuda K, Japanese Circulation Society Joint Working G (2020) JCS 2020 guideline on diagnosis and treatment of cardiac amyloidosis. Circ J 84:1610–1671 - DOI - PubMed
-
- Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, Burazor I, Caforio ALP, Damy T, Eriksson U, Fontana M, Gillmore JD, Gonzalez-Lopez E, Grogan M, Heymans S, Imazio M, Kindermann I, Kristen AV, Maurer MS, Merlini G, Pantazis A, Pankuweit S, Rigopoulos AG, Linhart A (2021) Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC working group on myocardial and pericardial diseases. Eur Heart J 42:1554–1568 - DOI - PubMed - PMC
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Research Materials